Axovant Reports Dosing of its First Patient in AXO-Lenti-PD study for Parkinson’s Disease at NIHR, UCLH

 Axovant Reports Dosing of its First Patient in AXO-Lenti-PD study for Parkinson’s Disease at NIHR, UCLH

Axovant Reports Dosing of its First Patient in AXO-Lenti-PD study for Parkinson’s Disease at NIHR, UCLH

Shots:

  • The ongoing AXO-Lenti-PD (also known OXB-102) study evaluates efficacy, safety, tolerability and measuring motor function in patients with PD. The closure of initial results from study is expected in H1’19
  • The trial is based on results of P-I/II trial of ProSavin for its safety and efficacy, demonstrating reductions in UPDRS Part III “OFF” scores for up to 6yrs. and is presented at Annual Congress of ESGCT18
  • AXO-Lenti-PD is a novel gene therapy allowing expression of three enzymes for dopamine synthesis in the brain. In 2018, Axovant gained rights for AXO-Lenti-PD therapy from Oxford BioMedica

Click here to read full press release/ article | Ref: Oxford Biomedica | Image: Talk markets

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post